text.skipToContent text.skipToNavigation
Need help? Please contact us

Human Coronary Artery Endothelial Cell Nucleofector™ Kit

Human Coronary Artery Endothelial Cell Nucleofector™ Kit

Catalog #: VPB-1001
For efficient transfection of primary HCAECs in the NucleofectorTM 2b Device
Compare

607.00 USD
ST

Product Overview

The Nucleofector® 2b System (or older generations I or II) works cell type specific kits, each of them dedicated to an individual primary cell. This Nucleofector® Kit is the optimal kit for efficient transfection of primary human coronary artery endothelial cells (HCAECs).

The respective cell type-specific Optimized Protocol or recommendation is available under "Instructions" or in our knowledge database. In this Optimized Protocol the best Nucleofection conditions are indicated. In addition, we share our experience and knowledge for treatment of this cell type.

 

Request More Info

Benefits

  • High transfection efficiencies for primary cells
  • Cells maintain functionality post transfection

Applications

  • Transfection of cell numbers in the range of 2 × 105 to 2 × 107 cells
  • Low-throughput transfection in single cuvette format

Storage and Content

2.25 mL Nucleofector® Solution for Human Coronary Artery Endothelial Cells
0.5 mL Supplement 4
30 µg pmaxGFPTM Vector (0.5 μg/μl in 10 mM Tris pH 8.0)
25 Aluminum cuvette (100 µL)
25 Single use pipettes

Return to Top

SDS, CoA, and Instructions

Safety Data Sheets (SDS)

Choose a language to view the SDS.

Certificate of Analysis (CoA)

Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.

Return to Top

Subscribe to our eNewsletter

Keep up to speed on the latest scientific developments, events, tips and tools from Lonza.

Interested in our webinars?

Need a break from your daily routine? Grab a coffee and check out our free webinars. 

Knowledge Center

Need technical data?

Browse our Cell and Transfection, Citation, FAQ and Culture Media Technical Databases.